



ZANUBRUTINIB

Title	Presenting Author	Date / Time (PST)	Location
<p>POSTER PRESENTATION (#3249) Sustained superiority of zanubrutinib vs bendamustine + rituximab in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL): 5-year follow-up of cohort 1 from the SEQUOIA study</p>	Mazyar Shadman	Sunday, December 8, 2024 6 - 8 PM	Convention Center, Halls G-H Session 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II
<p>POSTER PRESENTATION (#3255) Deep and sustained responses in patients with CLL treated with zanubrutinib or zanubrutinib + obinutuzumab in phase 1/2 AU-003 and phase 1b GA-101 studies: A report from the zanubrutinib extension study</p>	Constantine S. Tam	Sunday, December 8, 2024 6 - 8 PM	Convention Center, Halls G-H Session 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II
<p>POSTER PRESENTATION (#3029) Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: Growth modulation index analysis from ROSEWOOD study</p>	Judith Trotman	Sunday, December 8, 2024 6 - 8 PM	Convention Center, Halls G-H Session 623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II
<p>POSTER PRESENTATION (#3031) Long-term clinical outcomes in patients with Waldenström macroglobulinemia (WM) who received zanubrutinib in the phase 3 ASPEN study: A report from the zanubrutinib extension study</p>	Shirley D'Sa	Sunday, December 8, 2024 6 - 8 PM	Convention Center, Halls G-H Session 623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II
<p>POSTER PRESENTATION (#3257.1) CELESTIAL-TNCLL: An Ongoing, Open-Label, Multiregional, Phase 3 Study of Sonrotoclax (BGB-11417) + Zanubrutinib vs Venetoclax + Obinutuzumab for Treatment-Naïve CLL</p>	Piers Patten	Sunday, December 8, 2024 6 PM-8 PM	Halls G-H (San Diego Convention Center) Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II
<p>ORAL PRESENTATION (#986) Final analysis of a phase 1 study of zanubrutinib plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma</p>	Zheng Song	Monday, December 9, 2024 4:45 PM (4:30 - 6 PM)	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19 Session 627. Aggressive Lymphomas: Pharmacologic Therapies: Chemo-free Combinations for Relapsed Aggressive Lymphomas
<p>POSTER PRESENTATION (#4632) Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies</p>	Mazyar Shadman	Monday, December 9, 2024 6 - 8 PM	Convention Center, Halls G-H Session 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III
<p>POSTER PRESENTATION (#4412) Long-term impact of dose interruptions (DIs) of Bruton tyrosine kinase</p>	Judith Trotman	Monday, December 9, 2024 6 - 8 PM	Convention Center, Halls G-H Session 623. Mantle Cell, Follicular, Waldenstrom's, and Other



SONROTOCLAX

Title	Presenting Author	Date / Time (PST)	Location
POSTER PRESENTATION (#1661.1) BGB-11417-203, an Ongoing, Phase 2 Study of Sonrotoclax (BGB-11417), a Next-Generation BCL2 Inhibitor, in Patients With Waldenström Macroglobulinemia	Hui-Peng Lee	Saturday, December 7, 2024 5:30 PM-7:30 PM	Halls G-H (San Diego Convention Center) Session: 623. Mantle Cell, Follicular, Waldenström's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I
POSTER PRESENTATION (#3257.1) CELESTIAL-TNCLL: An Ongoing, Open-Label, Multiregional, Phase 3 Study of Sonrotoclax (BGB-11417) + Zanubrutinib vs Venetoclax + Obinutuzumab for Treatment-Naïve CLL	Piers Patten	Sunday, December 8, 2024 6 PM-8 PM	Halls G-H (San Diego Convention Center) Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II
ORAL PRESENTATION (#1012) Sonrotoclax and zanubrutinib as frontline treatment for CLL demonstrates high MRD clearance rates with good tolerability: Data from an ongoing phase 1/1b study BGB-11417-101	Jacob D. Soumerai	Monday, December 9, 2024 5:15 PM (4:30 - 6 PM)	Marriott Grand Ballroom 8-9 Session 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Targeted Therapy Combinations



BGB-16673

Title	Presenting Author	Date / Time (PST)	Location
POSTER PRESENTATION (#1649) Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory (R/R) indolent NHL: Results from the phase 1 CaDAnCe-101 study	Constantine S. Tam	Saturday, December 7, 2024 5:30 - 7:30 PM	Convention Center, Halls G-H Session 623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I
ORAL PRESENTATION (#860) Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory Waldenström macroglobulinemia: Results from the phase 1 CaDAnCe-101 study (<i>Encore of IWWM 2024</i>)	John F. Seymour	Monday, December 9, 2024 3:00 PM (2:45 - 4:15 PM)	Marriott Grand Ballroom 11-13 Session 623. MCL, FL, WM, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Clinical Trials for MZL, WM and HCL
ORAL PRESENTATION (#885) Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase 1 CaDAnCe-101 study	Meghan C. Thompson	Monday, December 9, 2024 3:15 PM (2:45 - 4:15 PM)	Marriott Grand Ballroom 5-6 Session 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Treating Refractory Disease-Novel Agents and Quality-of-Life
ONLINE ABSTRACT (#5833) BGB-16673, a selective BTK degrader, exhibits deeper inhibition of cancer cell signaling pathways and better efficacy in MCL models	Haitao Wang		



REAL-WORLD EVIDENCE

Title	Presenting Author	Date / Time (PST)	Location
<p>POSTER PRESENTATION (#2265) Prospective patient preference study for Bruton tyrosine kinase inhibitor (BTKi) treatment attributes and factors affecting patient shared decision-making chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in the United States (USA)</p>	Sikander Ailawadhi	Saturday, December 7, 2024 5:30 - 7:30 PM	Convention Center, Halls G-H Session 902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster I
<p>POSTER PRESENTATION (#2353) Real-world Bruton tyrosine kinase inhibitor (BTKi) utilization and clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)</p>	Jing-Zhou Hou	Saturday, December 7, 2024 5:30 - 7:30 PM	Convention Center, Halls G-H Session 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I
<p>POSTER PRESENTATION (#3732) Evaluating reasons for differences in real-world (RW) clinical outcomes among patients with relapsed/refractory mantle cell lymphoma (R/R MCL) on covalent BTK inhibitors (cBTKis)</p>	Tycel Phillips	Sunday, December 8, 2024 6 - 8 PM	Convention Center, Halls G-H Session 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II
<p>POSTER PRESENTATION (#3655) Patient medication preferences in follicular lymphoma (FL) in the United States (USA): A discrete choice experiment (DCE)</p>	Sameh Gaballa	Sunday, December 8, 2024 6 - 8 PM	Convention Center, Halls G-H Session 902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster II
<p>POSTER PRESENTATION (#5097) Impact of novel therapies (NTs) on real-world (RW) clinical outcomes of patients (pts) with relapsed/refractory (R/R) mantle-cell lymphoma (MCL) by race/ethnicity and TP53 mutation status</p>	Tycel Phillips	Monday, December 9, 2024 6 - 8 PM	Convention Center, Halls G-H Session 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster III
<p>ONLINE ABSTRACT (#7763) Treatment with zanubrutinib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were previously treated with another Bruton tyrosine kinase inhibitor in a US community oncology setting</p>	David Andorsky		



PRE-CLINICAL

Title	Presenting Author	Date / Time (PST)	Location
POSTER PRESENTATION (#4790) iPSC-derived CAR- γ δ T with SOCS1/CISH/BIM/FAS Combinatorial KO Demonstrated Extended Longevity and Profound Anti-tumor Efficacy Without Cytokine Support in Preclinical Studies	Jhang-Sian Yu	Saturday, December 7, 2024 5:30 - 7:30 PM	Convention Center, Halls G-H Session 702. CAR-T Cell Therapies: Basic and Translational: Poster III